Anniversary Timeline

25th Years of Innovation

2007

2007: Trabectedin (ET-743, Yondelis®) first anti-cancer drug from marine origins approved in Europe

Nominated by: Spanish Bioindustry Association – AseBio  Organisation in nomination: Pharmamar (Spain)              Marine environments are considered more biologically diverse than..Read More

2006

2006: Revolution in HIV treatment. First EMA approval for single tablet regimen taken once a day

Nominated by: Gilead Sciences Organisation in nomination: Gilead Sciences Antiretroviral therapy (ART) has played an instrumental role in the treatment of HIV, increasing the life expectancy..Read More

2006

2006: Globally accessible Gene Sequencing Technology

Nominated by: UK BioIndustry Association  Organisation in nomination: Solexa: Professor Sir Shankar Balasubramanian and Professor Sir David Klenerman Following establishment of UK SME Solexa in 1997, Professor Sir..Read More

2005

2005: Europe’s largest medicines biotechnology facilities open: Pfizer Grange Castle, Dublin

Nominated by: Pfizer  Organisations in nomination: Pfizer The Pfizer Grange Castle Biotechnology facility commenced construction in 2000 and was licensed and officially opened in 2005.  It..Read More

2003

2003: Human Genome Project completion

Nominated by: Voisin Consulting Life Sciences Launched in 1990, the Human Genome project was an unprecedented international scientific research project with the primary goal to discover..Read More

2003

2003: Targeting regulation of protein production for new medicines

Nominated by: PTC Therapeutics Organisation in nomination: PTC Therapeutics Diseases associated with protein disorders, such as Duchenne muscular dystrophy and spinal muscular atrophy have long been..Read More

2002

CRISPR-Cas genome editing technology

Nominated by: Spanish Bioindustry Association – AseBio, Lithianian Biotechnology Association   People in nomination: Professor Francisco Martinez Mojica, Department of Physiology, Genetics and Microbiology, University of..Read More

2001

2001: First enzyme replacement therapy for to treat Fabry disease approved in the European Union, plus world’s largest database of Fabry disease patients

Nominated by: Sanofi Organisation in nomination: Sanofi Genzyme Fabry disease (also Anderson–Fabry) disease, is a rare and heritable genetic disorder. The genetic fault behind the disease..Read More

2000

2000: Provitamin A enriched “Golden Rice” to combat vitamin A deficiency and blindness

Nominated by: Scienceindustries Switzerland  Organisation in nomination: Swiss Federal Institute of Technology, University of Freiburg    In 2000, the research teams of Ingo Potrykus (Swiss Federal..Read More

  • EV Biotech
  • Inscripta Inc.
  • Abolis
  • Health & Life Sciences cluster Bulgaria
  • Olon Group
  • MabDesign
  • Remilk
  • Bioeconomy for Change
 

BIOTECH NEWSLETTER


Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
 

BIOTECH NEWSLETTER


Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
Become a member